Mathilde Leclercq

553 total citations
34 papers, 321 citations indexed

About

Mathilde Leclercq is a scholar working on Ophthalmology, Rheumatology and Physiology. According to data from OpenAlex, Mathilde Leclercq has authored 34 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Ophthalmology, 5 papers in Rheumatology and 5 papers in Physiology. Recurrent topics in Mathilde Leclercq's work include Ocular Diseases and Behçet’s Syndrome (15 papers), Retinal and Optic Conditions (12 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). Mathilde Leclercq is often cited by papers focused on Ocular Diseases and Behçet’s Syndrome (15 papers), Retinal and Optic Conditions (12 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). Mathilde Leclercq collaborates with scholars based in France, Belgium and Australia. Mathilde Leclercq's co-authors include Julien Jacques, André Collet, David Saadoun, Bahram Bodaghi, P. Cacoub, Georgina Maalouf, Sara Touhami, F. Domont, J. Gueudry and A.C. Desbois and has published in prestigious journals such as Ophthalmology, Tetrahedron and Epilepsia.

In The Last Decade

Mathilde Leclercq

28 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mathilde Leclercq France 10 139 53 45 41 35 34 321
Emma Sala Italy 13 8 0.1× 47 0.9× 28 0.6× 76 1.9× 26 0.7× 53 555
Tetsuya Tanabe Japan 12 4 0.0× 11 0.2× 68 1.5× 43 1.0× 25 0.7× 65 480
Marianne Koch Austria 13 41 0.3× 91 1.7× 15 0.3× 12 0.3× 5 0.1× 42 529
Marjut Timonen Finland 12 4 0.0× 32 0.6× 56 1.2× 20 0.5× 64 1.8× 19 360
Richard Norman Canada 9 278 2.0× 3 0.1× 6 0.1× 9 0.2× 14 0.4× 29 528
C. Fernández United States 10 6 0.0× 4 0.1× 27 0.6× 33 0.8× 22 0.6× 15 433
B. S. Yamanashi United States 12 44 0.3× 3 0.1× 35 0.8× 29 0.7× 80 2.3× 22 403
Richard L. Cooper Australia 16 446 3.2× 5 0.1× 19 0.4× 6 0.1× 4 0.1× 49 671
Jeffrey A. Clanton United States 14 123 0.9× 1 0.0× 62 1.4× 18 0.4× 55 1.6× 24 875
Sanjay Patel United States 8 55 0.4× 6 0.1× 26 0.6× 4 0.1× 8 0.2× 29 288

Countries citing papers authored by Mathilde Leclercq

Since Specialization
Citations

This map shows the geographic impact of Mathilde Leclercq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathilde Leclercq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathilde Leclercq more than expected).

Fields of papers citing papers by Mathilde Leclercq

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathilde Leclercq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathilde Leclercq. The network helps show where Mathilde Leclercq may publish in the future.

Co-authorship network of co-authors of Mathilde Leclercq

This figure shows the co-authorship network connecting the top 25 collaborators of Mathilde Leclercq. A scholar is included among the top collaborators of Mathilde Leclercq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathilde Leclercq. Mathilde Leclercq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noël, Nicolas, Jean M. Schmidt, Achille Aouba, et al.. (2025). Comparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study. Journal of Neurology. 272(8). 531–531.
2.
Rheims, Sylvain, Florence Busato, Stanislas Lagarde, et al.. (2025). Extracellular vesicle microRNAs are biomarkers of focal epilepsy but not epilepsy‐related respiratory dysfunction. Epilepsia. 67(1). 408–423.
3.
4.
Leclercq, Mathilde, P. Sève, Lucie Biard, et al.. (2024). Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis. British Journal of Ophthalmology. 109(1). 34–40. 2 indexed citations
5.
Desbois, A.C., F. Domont, Amine Ghembaza, et al.. (2023). Behçet’s Disease Uveitis. Journal of Clinical Medicine. 12(11). 3648–3648. 3 indexed citations
6.
Desbois, A.C., F. Domont, Amine Ghembaza, et al.. (2023). Behçet's disease uveitis. La Revue de Médecine Interne. 44(10). 546–554. 1 indexed citations
7.
Maalouf, Georgina, Alban Deroux, Carlo Salvarani, et al.. (2023). Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients. The Journal of Rheumatology. 50(7). 916–923. 12 indexed citations
8.
Touhami, Sara, J. Gueudry, Mathilde Leclercq, et al.. (2021). Perspectives for immunotherapy in noninfectious immune mediated uveitis. Expert Review of Clinical Immunology. 17(9). 977–989. 9 indexed citations
9.
Leclercq, Mathilde, et al.. (2021). Differential Diagnosis of Vitritis in Adult Patients. Ocular Immunology and Inflammation. 29(4). 786–795. 4 indexed citations
10.
Leclercq, Mathilde, Georgina Maalouf, P. Sève, et al.. (2021). Anti–Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema. Ophthalmology. 129(5). 520–529. 45 indexed citations
11.
Cross, J. Helen, Μαρία Γώγου, Mathilde Leclercq, et al.. (2021). Classification of complications of epilepsy surgery and invasive diagnostic procedures: A proposed protocol and feasibility study. Epilepsia. 62(11). 2685–2696. 6 indexed citations
12.
Comarmond, C., Mathilde Leclercq, Gaëlle Leroux, et al.. (2020). 2019 Novel Coronavirus Disease (COVID-19) in Patients with Large-Vessels Vasculitis: Single-centre Experience in Paris. HAL (Le Centre pour la Communication Scientifique Directe). 72. 2–2. 1 indexed citations
13.
Leclercq, Mathilde, Vincent Langlois, N. Girszyn, et al.. (2020). Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis. Journal of Autoimmunity. 113. 102481–102481. 15 indexed citations
14.
Abad, Catalina, Mathilde Leclercq, Laetitia Jean, et al.. (2019). Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation. Journal of Neuroinflammation. 16(1). 64–64. 39 indexed citations
15.
Leclercq, Mathilde, M. Le Besnerais, Vincent Langlois, et al.. (2018). Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review. Clinical Rheumatology. 37(3). 849–853. 16 indexed citations
16.
Pradat, Pierre, Victor Virlogeux, Marianne Maynard, et al.. (2015). Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy. Hepatitis Monthly. 15(9). e28879–e28879. 1 indexed citations
17.
Leclercq, Mathilde & Isabelle Marié. (2014). Arterial thoracic outlet syndrome. Lara D. Veeken. 54(1). 44–44. 2 indexed citations
18.
Pirson, Michael, et al.. (2013). Financial consequences of hospital-acquired bacteraemia. Vol. 31(1). 3–13.
19.
Pirson, Michael, et al.. (2007). Financial consequences of hospital-acquired bacteraemia in three Belgian hospitals in 2003 and 2004. Journal of Hospital Infection. 68(1). 9–16. 17 indexed citations
20.
Bourgeois, Denis, et al.. (1993). The application of the theoretical model WHO/FDI planning system to an industrialised country: France.. PubMed. 43(1). 50–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emma Sala Breakdown of academic impact, for papers by Tetsuya Tanabe Breakdown of academic impact, for papers by Marianne Koch Breakdown of academic impact, for papers by Marjut Timonen Breakdown of academic impact, for papers by Richard Norman Breakdown of academic impact, for papers by C. Fernández Breakdown of academic impact, for papers by B. S. Yamanashi Breakdown of academic impact, for papers by Richard L. Cooper Breakdown of academic impact, for papers by Jeffrey A. Clanton Breakdown of academic impact, for papers by Sanjay Patel
Rankless by CCL
2026